Discovery of New Highly Potent Histamine H3 Receptor Antagonists, Calcium Channel Blockers, and Acetylcholinesterase Inhibitors

ACS Chem Neurosci. 2024 Sep 18;15(18):3363-3383. doi: 10.1021/acschemneuro.4c00341. Epub 2024 Aug 29.

Abstract

At present, one of the most promising strategies to tackle the complex challenges posed by Alzheimer's disease (AD) involves the development of novel multitarget-directed ligands (MTDLs). To this end, we designed and synthesized nine new MTDLs using a straightforward and cost-efficient one-pot Biginelli three-component reaction. Among these newly developed compounds, one particular small molecule, named 3e has emerged as a promising MTDL. This compound effectively targets critical biological factors associated with AD, including the simultaneous inhibition of cholinesterases (ChEs), selective antagonism of H3 receptors, and blocking voltage-gated calcium channels. Additionally, compound 3e exhibited remarkable neuroprotective activity against H2O2 and Aβ1-40, and effectively restored cognitive function in AD mice treated with scopolamine in the novel object recognition task, confirming that this compound could provide a novel and innovative therapeutic approach for the effective treatment of AD.

Keywords: Alzheimer’s disease; Biginelli reaction; calcium channels; cholinesterase; histamine H3 receptor; neuroprotection.

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Animals
  • Calcium Channel Blockers* / pharmacology
  • Cholinesterase Inhibitors* / chemical synthesis
  • Cholinesterase Inhibitors* / chemistry
  • Cholinesterase Inhibitors* / pharmacology
  • Drug Discovery / methods
  • Histamine H3 Antagonists* / chemistry
  • Histamine H3 Antagonists* / pharmacology
  • Humans
  • Male
  • Mice
  • Neuroprotective Agents / pharmacology

Substances

  • Cholinesterase Inhibitors
  • Calcium Channel Blockers
  • Histamine H3 Antagonists
  • Neuroprotective Agents